Teladoc Health Inc TDOC shares are trading lower in Tuesday's after-hours session after the company reported fourth-quarter results and issued weak guidance.
What Happened: Teladoc said fourth-quarter revenue increased 15% year-over-year to $637.71 million, which beat average analyst estimates of $633.65 million, according to Benzinga Pro. The company reported quarterly earnings of $23.49 per share due to non-cash goodwill impairment charges of $23.26 per share.
Excluding the impairment charge, Teladoc's net loss came in at 23 cents per share versus consensus estimates for a loss of 25 cents per share.
"Despite a challenging macro environment, we were able to expand our product offerings and enhance the level of care delivered across our integrated whole-person platform," said Jason Gorevic, CEO of Teladoc Health.
"As we look ahead to 2023, we see a healthy demand for solutions that promise better access and outcomes while lowering the cost of healthcare."
Teladoc sees first-quarter revenue in a range of $610 million to $625 million versus the $648.72 million estimate. The company anticipates a quarterly net loss of 45 cents to 55 cents per share versus an estimated loss of 43 cents.
Full-year 2023 revenue is expected to be between $2.55 billion and $2.675 billion. Teladoc expects a full-year net loss of $1.25 to $1.75 per share.
TDOC Price Action: Teladoc shares are down 9.51% after hours at $26.64 at the time of publication, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
